News und Analysen
Sensorion to participate in Chardan’s Annual Genetic Medicines & Cell Therapy Manufacturing Summit and Kempen’s Life Sciences Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, is pleased to announce its participation
EQS-News: Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications
EQS-News: Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms
EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
EQS-News: Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients
EQS-News: Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
EQS-News: Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
EQS-News: Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
Abivax postpones the publication of its 2023 Universal Registration Document
Abivax postpones the publication of its 2023 Universal Registration Document
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
MD Medical Group Investments Plc: MD Medical Group announces operating results for Q1 2023
MD Medical Group Investments Plc: MD Medical Group announces operating results for Q1 2023
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-News: MPH Health Care AG: Preliminary IFRS result 2022
EQS-News: MPH Health Care AG: Preliminary IFRS result 2022
EQS-News: Formycon publishes results for financial year 2022
EQS-News: Formycon publishes results for financial year 2022
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
MD Medical Group Investments Plc: The results of the Annual General Meeting of shareholders
MD Medical Group Investments Plc: The results of the Annual General Meeting of shareholders
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-Adhoc: Vita 34 AG publishes outlook for the 2023 financial year
EQS-Adhoc: Vita 34 AG publishes outlook for the 2023 financial year
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc